Eradivir

Executive Summary

Eradivir is a private biotechnology company pioneering a novel class of antibody-recruiting small molecules through its Bispecific Antigenic immuno-Therapy (BAiT) platform. This platform creates small molecules that selectively bind to diseased cells and recruit the patient's own antibodies to mark them for immune destruction. The company is initially focused on viral infections, with a lead program targeting influenza. Eradivir's approach offers potential advantages over traditional antiviral therapies, including broad-spectrum activity and reduced risk of resistance, as it leverages the host immune system. While still in preclinical development, the company has demonstrated proof-of-concept in vitro and in animal models, and is advancing toward IND-enabling studies. The platform's versatility also suggests potential expansion into other infectious diseases and oncology. Key risks include early stage, lack of clinical data, and the inherent challenges of translating novel mechanisms to the clinic.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead influenza program65% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal75% success